Ona Therapeutics Raises $86.6 Million Series B co-led by Columbus Venture Parrners and Mérieux Equity Partners to Advance First-in-Class ADCs into Clinical Development

by Columbus Venture Partners

The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life...

Read more

Columbus Venture Partners and Concentric co-lead a funding round in Visium to accelerate AI adoption in the pharmaceutical and biotechnology industries

by Columbus Venture Partners

Visium has grown to a team of 100 AI experts across Europe and has delivered more than 250 AI and data solutions for global leaders in life sciences, specialty chemicals and other regulated industries...

Read more

Columbus Venture Partners and ABE Capital Partners acquire a majority stake in Sermes CRO

by Columbus Venture Partners

Sermes CRO is a Spanish contract research organization (CRO) with 29 years of experience, dedicated to optimizing clinical research processes for pharmaceutical and biotechnology companies, as well as...

Read more

Columbus Venture Partners successfully completes the sale of Syngoi Technologies to U.S. based Artis BioSolutions

by Columbus Venture Partners

Syngoi Technologies has developed in recent years its own enzymatic synthetic DNA platform, designed to address one of the key structural challenges in the gene and cell therapy industry: the efficien...

Read more

Columbus Venture Partners participates in a $12.7M seed round of Accipiter Biosciences

by Columbus Venture Partners

The company has developed an advanced computational platform, combined with high-throughput experimentation, that uses proprietary methods to design multifunctional de novo proteins. These proteins, b...

Read more

ARTHEx Biotech Upsizes Series B Financing Round to $87 millones

by Columbus Venture Partners

The Series B extension financing was led by Bpifrance and joined by all existing shareholders, including AdBio Partners, CDTI Innovación, Columbus Venture Partners, European Innovation Council (EIC),...

Read more

Columbus Venture Partners launches the Columbus Life Sciences Fund V with a target of €200 million

by Columbus Venture Partners

Columbus Life Sciences Fund V will primarily invest in European and U.S.-based technology companies in the fields of biotechnology, advanced therapies, medical devices, precision medicine, diagnostics...

Read more

Highlight Therapeutics, a portfolio company of Columbus Venture Partners, and the CNIO launch their seventh clinical trial in advanced skin cancer

by Columbus Venture Partners

The Columbus Venture Partners team, strategic investor in the development of BO-112, celebrates this new clinical milestone as a validation of the company’s scientific and business strategy, while a...

Read more

Biotech firm Deepull raises €50 million in round led by Columbus Venture partners

by Columbus Venture Partners

The round was co-led by prominent investors Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners. The financing round also had strong participation from existing investors Asabys...

Read more

Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness

by Columbus Venture Partners

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, today announced that it has secured a $30 million fin...

Read more

Innovación y capital se dan cita en el ‘II Columbus Investor Day’ para impulsar el futuro de la biotecnología y la salud global

by Columbus Venture Partners

Esta cita, única en España, ha concentrado el foco de atención en torno a la inteligencia artificial (IA) aplicada a la salud debido al enorme potencial para revolucionar el diagnóstico, tratamien...

Read more

Tolerance Bio closes a $17.2 million round with the participation of Columbus and Criteria

by Columbus Venture Partners

Tolerance Bio is developing an allogeneic, or “off the shelf,” thymus induced pluripotent stem cell (iPSC)-based cell therapy platform as well as pharmacological thymus therapies to address immune...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

M&A and transport and logistics: resilie...

by Albia Capital Partners

The first quarter of 2026 has reinforced a clear reality in the transp...

Photos Stream